Zepbound (tirzepatide) side effects: the label-anchored rundown

Zepbound is the obesity-indication brand of tirzepatide, the once-weekly GIP/GLP-1 receptor agonist from Eli Lilly. Its side-effect profile is not a matter of anecdote: it is written down, in numbers, in the FDA prescribing information and in the pivotal SURMOUNT-1 trial that supported approval. This page is the label-anchored rundown — what is common, when it tends to happen, and the serious warnings that deserve real attention. For the broader class-wide picture of stomach symptoms, see our GLP-1 GI side-effects timeline; here we stay specific to Zepbound and its actual label.

The common reactions, by the numbers

In the SURMOUNT-1 adverse-reaction tables reproduced in the Zepbound label, the most frequent events were gastrointestinal. Across the maintenance doses (5, 10 and 15 mg), nausea occurred in roughly 25–29% of participants, diarrhea in about 19–23%, vomiting in about 8–13%, and constipation in about 11–17%, compared with much lower rates on placebo.^[1][2]Beyond those four, the label lists abdominal pain and dyspepsia (each around 9–10%), injection-site reactions (about 6–8%), fatigue (about 5–7%), hypersensitivity reactions (about 5%), plus eructation (belching), hair loss, gastroesophageal reflux and flatulence.^[1] Most of these reactions were mild to moderate in severity.^[2]

The pattern is the signature of the incretin class: appetite and gut motility are exactly what these drugs act on, so the gut is where the side effects show up. Tirzepatide adds the GIP pathway on top of GLP-1, but that did not change the character of the reactions — nausea and diarrhea still dominate, as our Zepbound versus Wegovy comparison lays out.

The timeline: front-loaded, then easier

When these symptoms happen matters as much as how often. GI reactions cluster around the early weeks and around each dose increase, which is precisely why Zepbound is started at 2.5 mg — a dose intended for tolerability, not weight loss — and stepped up no faster than every four weeks.^[1] For most people the roughest stretch is the first weeks after starting or after a step-up, and symptoms ease once they settle at a maintenance dose. That is also why trying to rush the titration schedule tends to backfire with more nausea rather than faster results. If you are still working out how to begin treatment at all, our guide on how to get Zepbound covers the practical path.

The boxed warning: thyroid C-cell tumors

Zepbound carries the class boxed warning. In rats, tirzepatide caused dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures; it is not known whether Zepbound causes such tumors, including medullary thyroid carcinoma (MTC), in humans.^[1]Because of this, the drug is contraindicated in anyone with a personal or family history of MTC and in anyone with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).^[1] The label instructs counseling patients on symptoms of thyroid tumors, such as a neck mass, difficulty swallowing, hoarseness, or persistent shortness of breath.^[1]

The other serious warnings

Beyond the boxed warning, the prescribing information flags several uncommon but serious risks:

• Pancreatitis. Acute pancreatitis has been reported with GLP-1 receptor agonists and Zepbound; the drug should be discontinued if it is suspected. Persistent, severe abdominal pain (sometimes radiating to the back, with or without vomiting) is the warning sign.^[1]
• Gallbladder disease. Acute gallbladder disease has occurred in trials. In the weight-loss studies, cholelithiasis (gallstones) was reported in about 1.1% of Zepbound-treated patients versus 1% on placebo, and cholecystitis in about 0.7% versus 0.2%.^[1]
• Hypoglycemia. Zepbound alone is a low hypoglycemia risk, but concomitant use with insulin or an insulin secretagogue (e.g., a sulfonylurea) can increase the risk of hypoglycemia, including severe hypoglycemia; the dose of those medicines may need to be reduced.^[1]
• Acute kidney injury. There have been postmarketing reports of acute kidney injury, sometimes requiring hemodialysis, generally in the setting of dehydration from nausea, vomiting or diarrhea. Staying hydrated matters.^[1]
• Hypersensitivity. Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported; the drug should be stopped if a serious reaction occurs.^[1]
• Diabetic retinopathy. Zepbound has not been studied in patients with certain non-proliferative or proliferative diabetic retinopathy or macular edema; patients with a history of diabetic retinopathy should be monitored.^[1]

One note on completeness, in the interest of honesty: earlier Zepbound labeling included language on monitoring for suicidal behavior and ideation, but that item was removed in the February 2026 label update.^[1] Anyone experiencing new or worsening mood changes on any weight-management medication should still raise it with their clinician.

What does not show up as a “side effect” on the label

Two things people worry about are not classic adverse reactions but are worth understanding. The first is loss of muscle alongside fat: rapid weight loss on any GLP-1 drug includes some lean-mass loss, which is best countered with adequate protein and resistance training — we cover the evidence in GLP-1 and lean-mass loss. The second is the facial volume loss sometimes called “Ozempic face”, which is a consequence of losing weight quickly rather than a drug toxicity.

When to call a clinician

Common nausea that eases over the first weeks is expected. What is not routine — and warrants a prompt call — is severe or persistent abdominal pain (possible pancreatitis), relentless vomiting or diarrhea with signs of dehydration, right-upper-abdominal pain with fever or jaundice (possible gallbladder disease), symptoms of low blood sugar if you also take insulin or a sulfonylurea, or any signs of a serious allergic reaction such as swelling, hives or trouble breathing.^[1] None of this is medical advice for your situation; it is the label's own red-flag list, and it exists to be acted on.

The honest bottom line

For most people the realistic Zepbound experience is a few rocky weeks of gastrointestinal symptoms that the slow titration schedule is designed to blunt, followed by a more settled maintenance phase. The serious risks — thyroid C-cell tumors in rodents, pancreatitis, gallbladder disease, kidney injury from dehydration, hypersensitivity and hypoglycemia in combination therapy — are uncommon but real, and the contraindications around thyroid cancer history are absolute. Cost and access are a separate practical matter, covered in our Zepbound cost guide. Read the label, respect the titration, and treat the red-flag symptoms as red flags.